BG108399A - Ан'ибак'...риално 'р...д''во - Google Patents

Ан'ибак'...риално 'р...д''во Download PDF

Info

Publication number
BG108399A
BG108399A BG108399A BG10839903A BG108399A BG 108399 A BG108399 A BG 108399A BG 108399 A BG108399 A BG 108399A BG 10839903 A BG10839903 A BG 10839903A BG 108399 A BG108399 A BG 108399A
Authority
BG
Bulgaria
Prior art keywords
amino acids
use according
substances
antibacterial agent
fragments
Prior art date
Application number
BG108399A
Other languages
Bulgarian (bg)
English (en)
Inventor
Frank Mayer
Original Assignee
Novologix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10129870A external-priority patent/DE10129870A1/de
Application filed by Novologix Gmbh filed Critical Novologix Gmbh
Publication of BG108399A publication Critical patent/BG108399A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BG108399A 2001-04-30 2003-12-01 Ан'ибак'...риално 'р...д''во BG108399A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10121145 2001-04-30
DE10129870A DE10129870A1 (de) 2001-04-30 2001-06-21 Antibakterielles Mittel
PCT/EP2002/004410 WO2002087554A2 (de) 2001-04-30 2002-04-22 Ef-tu-bindende substanzen als ntibakterielles mittel

Publications (1)

Publication Number Publication Date
BG108399A true BG108399A (bg) 2004-08-31

Family

ID=26009202

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108399A BG108399A (bg) 2001-04-30 2003-12-01 Ан'ибак'...риално 'р...д''во

Country Status (17)

Country Link
EP (1) EP1397157A2 (es)
JP (1) JP2004534016A (es)
CN (1) CN1298739C (es)
AU (1) AU2002302555B2 (es)
BG (1) BG108399A (es)
BR (1) BR0209282A (es)
CA (1) CA2445995A1 (es)
CZ (1) CZ20033271A3 (es)
EE (1) EE200300530A (es)
HU (1) HUP0401586A3 (es)
IL (1) IL158627A0 (es)
MX (1) MXPA03009954A (es)
NZ (1) NZ529662A (es)
PL (1) PL366836A1 (es)
RU (1) RU2003134636A (es)
SK (1) SK14792003A3 (es)
WO (1) WO2002087554A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10229645A1 (de) * 2002-07-02 2004-05-19 Kuchenreuther, Ulrich, Dr. Zellaufschluss von Bakterien
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
ES2650665T3 (es) 2009-07-31 2018-01-19 Grünenthal GmbH Método de cristalización y biodisponibilidad
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN105218668B (zh) * 2015-10-30 2020-03-24 山东农业大学 马耳他型布氏杆菌的EF-Tu蛋白单克隆抗体MAb及其制备方法与应用
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466251A1 (en) * 1990-07-10 1992-01-15 Gist-Brocades N.V. Elfamycin-resistant mutants
EP1049809B1 (en) * 1998-01-23 2006-10-25 bioMerieux B.V. EF-Tu mRNA AS A MARKER FOR VIABILITY OF BACTERIA
US6451556B1 (en) * 1998-12-21 2002-09-17 Smithkline Beecham Corporation EF-Tu

Also Published As

Publication number Publication date
BR0209282A (pt) 2004-07-27
CA2445995A1 (en) 2002-11-07
SK14792003A3 (sk) 2004-07-07
EE200300530A (et) 2004-04-15
HUP0401586A2 (hu) 2004-11-29
HUP0401586A3 (en) 2005-06-28
EP1397157A2 (de) 2004-03-17
WO2002087554A2 (de) 2002-11-07
PL366836A1 (en) 2005-02-07
AU2002302555B2 (en) 2007-08-23
RU2003134636A (ru) 2005-04-20
WO2002087554A3 (de) 2003-01-30
WO2002087554B1 (de) 2005-01-27
CN1298739C (zh) 2007-02-07
IL158627A0 (en) 2004-05-12
NZ529662A (en) 2006-08-31
JP2004534016A (ja) 2004-11-11
CZ20033271A3 (en) 2004-06-16
CN1518455A (zh) 2004-08-04
MXPA03009954A (es) 2005-07-25

Similar Documents

Publication Publication Date Title
Lee et al. Structure–activity relationships of de novo designed cyclic antimicrobial peptides based on gramicidin S
Fleury et al. Covalent structure, synthesis, and structure-function studies of mesentericin Y 10537, a defensive peptide from Gram-positive bacteria Leuconostoc mesenteroides
Moura et al. Thanatin impairs lipopolysaccharide transport complex assembly by targeting LptC–LptA interaction and decreasing LptA stability
EP0690872B1 (en) Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
KR960705850A (ko) 사람 쿠니즈형 프로테아제 저해인자(human kunitz-type protease inhibitors)
SZTROLOVICS et al. Resistance of small leucine-rich repeat proteoglycans to proteolytic degradation during interleukin-1-stimulated cartilage catabolism
CN113717271A (zh) 新的多肽及其医疗用途
Shamova et al. Minibactenecins ChBac7. Nα and ChBac7. Nβ-antimicrobial peptides from leukocytes of the goat Capra hircus
BG108399A (bg) Ан'ибак'...риално 'р...д''во
US20240294572A1 (en) Antimicrobial Peptides
Acevedo et al. IsCT‐based analogs intending better biological activity
Sol et al. Actin enables the antimicrobial action of LL-37 peptide in the presence of microbial proteases
Mochizuki et al. Integrin‐dependent cell behavior on ECM peptide‐conjugated chitosan membranes
WO1999060016A2 (en) Antimicrobial cationic peptide derivatives of bactenecin
Schwan et al. Formation of nanotube-like protrusions, regulation of septin organization and re-guidance of vesicle traffic by depolymerization of the actin cytoskeleton induced by binary bacterial protein toxins
Porat et al. Acyl-substituted dermaseptin S4 derivatives with improved bactericidal properties, including on oral microflora
US20040235745A1 (en) Antimicrobial Peptides
Thomson et al. Mapping Hsp47 binding site (s) using CNBr peptides derived from type I and type II collagen
Won et al. Structure-activity relationships of antimicrobial peptides from the skin of Rana esculenta inhabiting in Korea
US20090048176A1 (en) Antibacterial agent
US7659366B2 (en) Peptide with putative role in cytoskeletal protection
Jia et al. Tryptic Stability and Antimicrobial Activity of the Derivatives of Polybia-CP with Fine-Tuning Modification in the Side Chain of Lysine
US20070298032A1 (en) Proteins Involved In Quorum Sensing
US20240165196A1 (en) Beta-Lactamase Inhibitors
Hanušová et al. Peptide fragments induce a more rapid immune response than intact proteins in earthworms